Target Price | $9.69 |
Price | $7.85 |
Potential |
23.44%
register free of charge
|
Number of Estimates | 8 |
8 Analysts have issued a price target Xeris Biopharma Holdings 2026 .
The average Xeris Biopharma Holdings target price is $9.69.
This is
23.44%
register free of charge
$11.55
47.13%
register free of charge
$6.06
22.80%
register free of charge
|
|
A rating was issued by 12 analysts: 10 Analysts recommend Xeris Biopharma Holdings to buy, 2 to hold and 0 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Xeris Biopharma Holdings stock has an average upside potential 2026 of
23.44%
register free of charge
|
Dec '24 |
2025 Estimates |
|
---|---|---|
Revenue Million $ | 203.07 | 292.20 |
23.89% | 43.89% | |
EBITDA Margin | -11.23% | 11.99% |
44.52% | 206.79% | |
Net Margin | -27.01% | -3.75% |
28.90% | 86.11% |
8 Analysts have issued a sales forecast Xeris Biopharma Holdings 2025 . The average Xeris Biopharma Holdings sales estimate is
This results in the following potential growth metrics:
5 Analysts have issued an Xeris Biopharma Holdings EBITDA forecast 2025. The average Xeris Biopharma Holdings EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
8 Xeris Biopharma Holdings Analysts have issued a net profit forecast 2025. The average Xeris Biopharma Holdings net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Dec '24 |
2025 Estimates |
|
---|---|---|
Earnings Per Share $ | -0.37 | -0.07 |
17.78% | 81.08% | |
P/E | negative | |
EV/Sales | 4.87 |
8 Analysts have issued a Xeris Biopharma Holdings forecast for earnings per share. The average Xeris Biopharma Holdings EPS is
This results in the following potential growth metrics and future valuations:
Xeris Biopharma Holdings...
Analyst | Rating | Action | Date |
---|---|---|---|
Oppenheimer |
Locked
➜
Locked
|
Locked | May 09 2025 |
HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Mar 07 2025 |
Piper Sandler |
Locked
➜
Locked
|
Locked | Mar 07 2025 |
HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Nov 11 2024 |
Piper Sandler |
Locked
➜
Locked
|
Locked | Nov 11 2024 |
Analyst Rating | Date |
---|---|
Locked
Oppenheimer:
Locked
➜
Locked
|
May 09 2025 |
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Mar 07 2025 |
Locked
Piper Sandler:
Locked
➜
Locked
|
Mar 07 2025 |
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Nov 11 2024 |
Locked
Piper Sandler:
Locked
➜
Locked
|
Nov 11 2024 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.